.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,088,368

« Back to Dashboard

Claims for Patent: 8,088,368

Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Mackman; Richard L. (Foster City, CA), Pyun; Hyung-Jung (Foster City, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/779,023
Patent Claims: 1. A compound of formula: ##STR01319## wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A.sup.15 is: ##STR01320## P is selected from: ##STR01321## ##STR01322## and R''' is hydrogen or methyl; or a pharmaceutically acceptable salt, or prodrug thereof.

2. The compound of claim 1 that is: ##STR01323## or a pharmaceutically acceptable salt, or prodrug thereof.

3. The compound of claim 1 that is: ##STR01324## or a pharmaceutically acceptable salt, or prodrug thereof.

4. The compound of claim 1 wherein P is selected from: ##STR01325##

5. The compound of claim 1 wherein P is ##STR01326##

6. The compound of claim 1 wherein P is ##STR01327##

7. The compound of claim 1 that is: ##STR01328## or a pharmaceutically acceptable salt, or prodrug thereof.

8. The compound of claim 1 that is: ##STR01329## or a pharmaceutically acceptable salt, or prodrug thereof.

9. A compound: ##STR01330## wherein: V is alkyl; M is a 5-membered heteroaryl ring; and A.sup.15 is: ##STR01331## or a pharmaceutically acceptable salt, or prodrug thereof.

10. A compound: ##STR01332## wherein V is alkyl; and A.sup.15 is: ##STR01333## or a pharmaceutically acceptable salt, or prodrug thereof.

11. The compound of claim 1 wherein each V is: ##STR01334##

12. A compound of formula: ##STR01335## or a pharmaceutically acceptable salt, or prodrug thereof.

13. A pharmaceutical composition comprising the compound as described in claim 1 or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, further comprising at least one additional therapeutic agent.

15. The pharmaceutical composition of claim 14, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

16. The pharmaceutical composition according to claim 13, further comprising a nucleoside analogue.

17. The pharmaceutical composition according to claim 16, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.

18. A compound of formula: ##STR01336## or a pharmaceutically acceptable salt, or prodrug thereof.

19. A pharmaceutical composition comprising the compound as described in claim 18 or a pharmaceutically acceptable salt, or prodrug thereof and at least one pharmaceutically acceptable carrier.

20. The pharmaceutical composition of claim 19, further comprising at least one additional therapeutic agent.

21. The pharmaceutical composition of claim 20, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

22. The pharmaceutical composition according to claim 19, further comprising a nucleoside analogue.

23. The pharmaceutical composition according to claim 22, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc